Ernexa Therapeutics (ERNA) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to -$1.2 million.
- Ernexa Therapeutics' Income towards Parent Company rose 9533.9% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.4 million, marking a year-over-year increase of 5913.92%. This contributed to the annual value of -$44.6 million for FY2024, which is 10564.43% down from last year.
- Latest data reveals that Ernexa Therapeutics reported Income towards Parent Company of -$1.2 million as of Q3 2025, which was up 9533.9% from -$3.1 million recorded in Q2 2025.
- Over the past 5 years, Ernexa Therapeutics' Income towards Parent Company peaked at -$1.2 million during Q3 2025, and registered a low of -$86.0 million during Q3 2021.
- Over the past 5 years, Ernexa Therapeutics' median Income towards Parent Company value was -$5.8 million (recorded in 2024), while the average stood at -$12.2 million.
- Per our database at Business Quant, Ernexa Therapeutics' Income towards Parent Company tumbled by 570594.19% in 2021 and then soared by 9533.9% in 2025.
- Ernexa Therapeutics' Income towards Parent Company (Quarter) stood at -$86.0 million in 2021, then surged by 94.78% to -$4.5 million in 2022, then tumbled by 37.07% to -$6.2 million in 2023, then grew by 6.08% to -$5.8 million in 2024, then soared by 78.54% to -$1.2 million in 2025.
- Its Income towards Parent Company was -$1.2 million in Q3 2025, compared to -$3.1 million in Q2 2025 and -$8.2 million in Q1 2025.